Business
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a neuroprotective candidate Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovatio
About this update from Oculis Holding Ag
[{"type":"image","alt":"Oculis Holding AG","displaySize":"","headline":null,"caption":"Oculis Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/idMDc2ICl_M_YqOf88DMVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9","width":300,"height":75},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/idMDc2ICl_M_YqOf88DMVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9","width":300,"height":75}},"lazy":false},{"type":"text","content":"ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) --","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a neuroprotective candidate ","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":324,"olType":false},{"type":"text","content":"Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.","length":757,"tagName":"p"},{"type":"text","content":"Privosegtor is a novel peptoid small molecule that crosses the blood-brain and retinal barriers; it has the potential to become the first neuroprotective th...